Teleflex (NYSE:TFX) announced today that it launched its UroLift system for treating benign prostatic hyperplasia (BPH) in Japan.
Wayne, Pennsylvania–based Teleflex made the UroLift system for BPH or enlarged prostate available for purchase immediately, having recently received reimbursements approval from the Central Social Insurance Medical Council of Japan (Chuikyo).
The company designed UroLift as a minimally invasive approach that can be performed as a same-day outpatient procedure, providing rapid symptom relief for men with BPH with quick recovery time.
“As we execute on our overseas expansion strategy for the UroLift system, Japan represents an important milestone in our progress,” Teleflex Chair, President and CEO Liam Kelly said in a news release. “The UroLift system offers clinical benefits in the minimally invasive treatment of BPH. Our commercialization in Japan marks another step in our goal to make this novel therapy more broadly available to men outside the United States suffering from BPH. Teleflex remains committed to its goal to make the UroLift system the standard of care in the treatment of BPH globally.”